Illumina Stock Is Up 133% This Year. Here’s Where It Could Go Further.

Illumina (ILMN) stock has surged 133% year-to-date, closing at $240 on September 18, 2026, after dipping to around $103 a year prior. Analysts rate the stock with 7 buy ratings, 4 outperform, 6 holds, 3 underperform and 1 sell, with the mean target at $203, 15% below current price. TIKR predicts a $270 value by December 2030. Director Keith Meister has sold over $255 million in shares since August.

Illumina's earnings post beat expectations in Q2, Q1 and Q4 2026, leading to raised guidance to $5.30-$5.40 adjusted EPS and organic revenue growth outlook above 5%. CEO Jacob Thaysen stated the clinical cliff is a wave, not a cliff, as sequencing demand compounding rather than fading. Illumina joined the S&P 500 in September, and Argus Research raised its price target to $235.

Insider disposals have topped $255 million in six weeks, adding supply to index-driven demand. Analysts' mean price target has risen nearly every quarter to $203 from $109 in June 2025, but the stock has outpaced each revision. Coverage thinned from 23 targets a year ago to 20 now, yet the stock remains a top mover. TIKR forecasts $270 by year-end, implying 13% total return, below average life-science tools returns. Analysts believe continued clinical conversion, not multiple expansion, will drive future gains.